Friday, September 28, 2012

Announcing IIR’s Data-Driven Drug Development Agenda

Big Data is transforming the way you do business and has the potential to improve R&D productivity, creating HUNDREDS OF BILLIONS OF DOLLARS in value. The data now available and the technologies developed to evaluate it have led to a systematic shift in how IT and R&D function, making the IM organization into a partner with the strategic business side of the industry.

IIR's Data-Driven Drug Development (D4) is the first life science information management event to focus on the strategic business challenges faced by IT and R&D leadership. You will get the knowledge you need to balance new technologies with emerging information disciplines to harness the data available for faster decision making to generate critical information for drug development.

Hear from leaders in R&D IT including:
  • - Angela Yochem, CTO, Astrazeneca
  • - Dan Woods, Contributor,, CTO & Editor,
  • - Ramzi Najm , VP, R&D Information & Technology Management, Allergan
  • - Matthew Dattillo, CIO, Cubist Pharmaceuticals

Attend D4 to unleash data’s potential to create billions of dollars in revenue and bridge the knowledge gap between R&D and IT:
  • • Create a “data scientist” in your organization and overcome the challenge of talent acquisition for the new R&D IT sector
  • • Drive scientific and business decisions through data structuring and mining
  • • Leverage IT’s rich history of governance and technology introduction to create a framework for external collaboration
  • • Integrate and network the growing amounts of data using innovative tools and applications
Data-Driven Drug Development will take place January 28-29, 2012 in Philadelphia. As a reader of this blog, you’ll save 15% off the standard rate when you register to join us and mention code XP1715LINK! If you have any questions about the program, feel free to email Jennifer Pereira.

Share this article with your social network, just click below to share now!

No comments :

Post a Comment